FIS Launches Its New Revenue Insight Solution to Transform Accounts Receivable Management and Optimize Collections

FIS Launches Its New Revenue Insight Solution to Transform Accounts Receivable Management and Optimize Collections

Key Facts

  • The FIS Revenue Insight solution harnesses artificial intelligence (AI) as it seeks to provide a comprehensive tool for giving actionable insights into cash at risk without manual, error-prone processes.

  • The patented solution enables finance teams across any industry to identify high-risk accounts, prioritize collection efforts and proactively manage cash flow across the money lifecycle.

  • The FIS Revenue Insight product empowers businesses to turn the office of the CFO from a cost center to a true strategic advantage by removing friction in money movement and creating revenue opportunities to help businesses grow.

JACKSONVILLE, Fla.–(BUSINESS WIRE)–FIS® (NYSE: FIS), a global leader in financial technology across the full money lifecycle, today announced the launch of FIS Revenue Insight, a predictive analytics solution designed to help businesses optimize collections. Through proprietary patented technology powered by artificial intelligence (AI), FIS Revenue Insight aims to deliver actionable insights into cash at risk, enabling companies to proactively identify risks, accelerate revenue and drive business growth.

The FIS Revenue Insight solution is part of the FIS Automated Finance suite, which delivers data-driven receivables automation, payables automation and revenue optimization solutions for the office of the CFO in any industry, enabling the seamless flow of money in motion.

Why Revenue Insight Matters

Today’s finance leaders across industries face growing pressure to modernize their accounts receivable management. According to a recent survey,1 81% of businesses have experienced an increase in delayed payments, with 50% experiencing late payments from customers and 77% of AR teams falling behind on their metrics. Even the best finance departments face questions about which accounts will or will not pay, and who will self-correct or who will go into severe delinquency.

The FIS Revenue Insight product can help CFOs bring technology harmony to the money lifecycle, employing AI to analyze customer data, identify high-risk accounts and address potential issues before they escalate. This tool uncovers patterns and trends that might go unnoticed by human analysis, allowing finance teams to shift from manual tasks to strategic activities and reduce days sales outstanding. Additionally, when paired with FIS’ award-winning GETPAID™ credit-to-cash solution, users may see enhanced cash flow and working capital optimization, deeper insights into portfolio risk and greater levels of automation. With the proprietary Revenue Insight scoring model, businesses can prioritize accounts that are at the highest risk of payment delays, ensuring their collection efforts are more targeted and efficient.

“Revenue Insight, as part of the FIS Automated Finance suite, can revolutionize the way CFOs manage cash flow in today’s fast-paced environment. Our vision is to provide systems that turn finance from a cost center into a growth partner, taking the friction out of finance through visibility, real-time insights and innovation that maximizes revenue and strengthens customer relationships,” said Seamus Smith, group president of Automated Finance, FIS. “A data-driven, proactive approach to accounts receivable management is critical for our clients to balance money in motion while maintaining a competitive edge and financial stability. With the help of Revenue Insight, our clients can take the guesswork out of collections.”

FIS Revenue Insight’s versatile application can benefit a broad range of sectors, including accounts receivables, financial institutions, supply chain financing, debt collectors, insurance premiums and utilities.

For more information on Revenue Insight, visit www.fisglobal.com/products/automated-finance.

About FIS

FIS is a financial technology company providing solutions to financial institutions, businesses and developers. We unlock financial technology to the world across the money lifecycle underpinning the world’s financial system. Our people are dedicated to advancing the way the world pays, banks and invests, by helping our clients to confidently run, grow and protect their businesses. Our expertise comes from decades of experience helping financial institutions and businesses of all sizes adapt to meet the needs of their customers by harnessing where reliability meets innovation in financial technology. Headquartered in Jacksonville, Florida, FIS is a member of the Fortune 500® and the Standard & Poor’s 500® Index. To learn more, visit FISglobal.com. Follow FIS on LinkedIn, Facebook and X.

1 American Express, Meeting the Growing Need for AR Modernization – The B2B and Digital Payments Tracker® Series

Kim Snider, 904.438.6278

Senior Vice President

FIS Global Marketing and Communications

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Data Management Banking Technology Professional Services Payments Other Technology Software Artificial Intelligence Mobile/Wireless Hardware Finance

MEDIA:

Logo
Logo

The Hartford Unveils Refreshed Brand With Modernized Stag Logo

The Hartford Unveils Refreshed Brand With Modernized Stag Logo

As part of the brand launch, company expands philanthropy programs, renames holding company and business segments

HARTFORD, Conn.–(BUSINESS WIRE)–The Hartford launched its new brand, featuring a bold, contemporary look for its iconic stag logo that honors the company’s rich history while demonstrating its modern, visionary spirit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250206857870/en/

Evolution of The Hartford's logo. (Photo: Business Wire)

Evolution of The Hartford’s logo. (Photo: Business Wire)

“As we embrace an ambitious growth-and-innovation strategy centered on our customers and their changing needs, our brand must evolve with the business,” said The Hartford’s Chairman and CEO Christopher Swift. “The new brand celebrates The Hartford’s strength, built on centuries of trust from the businesses, workers, and people we support every day. The modern design points to our bold future, inspired by innovation and a relentless focus on our customers.”

The company’s stag logo remains the centerpiece of the brand, symbolizing strength, confidence and resilience. The new design reflects the grandeur of “The Monarch of the Glen,” a painting completed in 1851 by Sir Edwin Landseer, which has been an inspiration for The Hartford’s logo since 1875. This modern representation showcases the stag looking over his herd and gazing confidently into the future.

“Our modernized brand is a representation of who we are as an insurance leader and how we demonstrate to customers, through our actions, that we prioritize their needs and uphold our commitments,” said The Hartford’s Chief Marketing and Communications Officer Claire Burns. “This is a valuable opportunity to create lasting impressions and deepen relationships with customers, employees and the world at large.”

The company updated its color palette and typography to create a vibrant new identity that leaves a memorable impact. The new core colors are – black for stability, claret for the company’s heritage, and fuchsia for modernity. Additionally, white and warm-gray will enhance the design of company materials, providing clarity and balance.

Starting today, the company’s brand will be visible to the public on TV, digital platforms and The Hartford’s refreshed website. Following the initial launch, the company will roll out advertising for specific business lines and continue to update its branding across platforms and materials over the next few years.

The Hartford worked with agency partners Pentagram and Solve to develop the refreshed brand identity and new campaign.

Philanthropy Focus On Small Businesses, Mental Health

As part of the refreshed brand, the company is increasing its annual philanthropy spending by more than 30%, to help support small businesses, revitalize main streets in historic downtown neighborhoods, and address mental health stigma in the workplace. This includes an expansion of the company’s Small Business Accelerator pilot with Main Street America (MSA), which creates commercial space and repurposes blighted storefronts helping small businesses with access to affordable commercial real estate and restoring vibrancy to communities. Over the next three years, in partnership with MSA, The Hartford will develop multi-use commercial space in 15 communities across the country benefiting 1,500 small businesses.

In addition, the company is expanding its partnership with Active Minds, providing mental health resources and support for the next generation of workers. This includes sponsorship of the Send Silence Packing® exhibit featuring 100 backpacks with 100 personal stories covering themes of loss, survival and resilience. With The Hartford’s support, Active Minds will bring the educational event to 60-80 colleges and communities this year, reaching more than half a million youth and young adults in the U.S.

Name Changes For Holding Company And Business Segments

In conjunction with the brand launch, The Hartford updated its holding company name to The Hartford Insurance Group, Inc., effective today. The company’s ticker symbol (NYSE: HIG) will not change and its common stock will begin trading on the New York Stock Exchange as The Hartford Insurance Group, Inc., on Feb. 18, 2025.

Additionally, some of the business segments will be renamed. Commercial Lines will become Business Insurance; Personal Lines will be Personal Insurance; and Group Benefits will be Employee Benefits. There is no change to Hartford Funds’ name.

About The Hartford

The Hartford is a leader in property and casualty insurance, group benefits and mutual funds. With more than 200 years of expertise, The Hartford is widely recognized for its service excellence, sustainability practices, trust and integrity. More information on the company and its financial performance is available at https://www.thehartford.com.

The Hartford Insurance Group, Inc., (NYSE: HIG) operates through its subsidiaries under the brand name, The Hartford, and is headquartered in Hartford, Connecticut. For additional details, please read The Hartford’s legal notice.

HIG-C

Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our 2023 Annual Report on Form 10-K, subsequent Quarterly Reports on Forms 10-Q, and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued.

From time to time, The Hartford may use its website and/or social media channels to disseminate material company information. Financial and other important information regarding The Hartford is routinely accessible through and posted on our website at https://ir.thehartford.com. In addition, you may automatically receive email alerts and other information about The Hartford when you enroll your email address by visiting the “Email Alerts” section at https://ir.thehartford.com.

Media:

Matthew Sturdevant

860-547-8664

[email protected]

Investor:

Susan Spivak Bernstein

860-547-6233

[email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Photo
Photo
Evolution of The Hartford’s logo. (Photo: Business Wire)
Photo
Photo
The Hartford’s new logo (Graphic: Business Wire)
Logo
Logo

Peabody Board Declares Dividend on Common Stock

PR Newswire


ST. LOUIS
, Feb. 6, 2025 /PRNewswire/ — Peabody (NYSE: BTU) announced today that its Board of Directors has declared a quarterly dividend on its common stock of $0.075 per share, payable on March 11, 2025 to stockholders of record on February 19, 2025.

Peabody is a leading coal producer, providing essential products for the production of affordable, reliable energy and steel. Our commitment to sustainability underpins everything we do and shapes our strategy for the future. For further information, visit PeabodyEnergy.com. 

Contact:

Vic Svec

[email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the securities laws. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words or variation of words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “targets,” “would,” “will,” “should,” “goal,” “could” or “may” or other similar expressions. Forward-looking statements provide management’s current expectations or predictions of future conditions, events or results. All statements that address operating performance, events, or developments that Peabody expects will occur in the future are forward-looking statements. They may include estimates of sales and other operating performance targets, cost savings, capital expenditures, dividends, share repurchases, other expense items, actions relating to strategic initiatives, demand for the company’s products, liquidity, capital structure, market share, industry volume, other financial items, descriptions of management’s plans or objectives for future operations and descriptions of assumptions underlying any of the above. The declaration and payment of future quarterly dividends remains at the discretion of the Board of Directors and will depend on the Company’s financial results, cash flow and cash requirements, future prospects, and other factors deemed relevant by the Board. All forward-looking statements speak only as of the date they are made and reflect Peabody’s good faith beliefs, assumptions and expectations, but they are not guarantees of future performance or events. Furthermore, Peabody disclaims any obligation to publicly update or revise any forward-looking statement, except as required by law. By their nature, forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Factors that might cause such differences include, but are not limited to, a variety of economic, competitive and regulatory factors, many of which are beyond Peabody’s control, that are described in Peabody’s Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and other factors that Peabody may describe from time to time in other filings with the SEC. You may get such filings for free at Peabody’s website at www.peabodyenergy.com. You should understand that it is not possible to predict or identify all such factors and, consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties. 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/peabody-board-declares-dividend-on-common-stock-302370155.html

SOURCE Peabody

Koppers Holdings Inc. Schedules Fourth Quarter and Full-Year 2024 Conference Call

PR Newswire


PITTSBURGH
, Feb. 6, 2025 /PRNewswire/ — Koppers Holdings Inc. (NYSE: KOP), an integrated global provider of treated wood products, wood treatment chemicals, and carbon compounds, today announced that the company plans to release its financial results for the fourth quarter and full-year 2024 before the market opens on Thursday, February 27, 2025, and discuss its outlook on a conference call later that day at 11:00 a.m. Eastern Time.  Presentation materials will be available at least 15 minutes before the call on www.koppers.com in the Investor Relations section of the company’s website.

Interested parties may access the live audio broadcast toll free by dialing 833-366-1128 in the United States and Canada, or 412-902-6774 for international, Conference ID number 10196723. Participants are requested to access the call at least five minutes before the scheduled start time to complete a brief registration.  The conference call will be broadcast live on  www.koppers.com and can also be accessed here.

An audio replay will be available approximately two hours after the completion of the call at 877-344-7529 for U.S. toll free, 855-669-9658 for Canada toll free, or 412-317-0088 for international, using replay access code 5314690. The recording will be available for replay through May 27, 2025.

About Koppers
Koppers (NYSE: KOP) is an integrated global provider of essential treated wood products, wood preservation technologies and carbon compounds. Our team of 2,100 employees create, protect and preserve key elements of our global infrastructure – including railroad crossties, utility poles, outdoor wooden structures, and production feedstocks for steel, aluminum and construction materials, among others – applying decades of industry-leading expertise while constantly innovating to anticipate the needs of tomorrow. Together we are providing safe and sustainable solutions to enable rail transportation, keep power flowing, and create spaces of enjoyment for people everywhere. Protecting What Matters, Preserving The Future. Learn more at Koppers.com.

Inquiries from the media should be directed to Ms. Jessica Franklin Black at [email protected] or 412-227-2025.  Inquiries from the investment community should be directed to Ms. Quynh McGuire at [email protected] or 412-227-2049.

For Information:   

Quynh McGuire, Vice President, Investor Relations

412 227 2049


[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/koppers-holdings-inc-schedules-fourth-quarter-and-full-year-2024-conference-call-302369625.html

SOURCE KOPPERS HOLDINGS INC.

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the U.S. and Europe

HYDERABAD, India–(BUSINESS WIRE)–
Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that it has entered into a license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) related to the development and commercialization of HLX15, Henlius’s investigational daratumumab biosimilar candidate to Darzalex® & Darzalex Faspro®.

HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection, with intravenous as well as subcutaneous formulations. HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro®*, which are indicated for the treatment of multiple myeloma.

The agreement combines Dr. Reddy’s global commercial presence with Henlius’ proven capabilities in developing biosimilars for markets worldwide. Under the terms of the agreement, Henlius will be responsible for development, manufacturing and commercial supply, and may receive up to a total of $131.6 million, including an upfront payment of $33 million and milestone payments. In addition, Henlius is eligible to receive royalties on annual net sales of the product. Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the United States (U.S.) and Europe.

Erez Israeli, Chief Executive Officer of Dr. Reddy’s, said: “We are pleased to collaborate with Henlius to make this daratumumab biosimilar available to patients in the U.S. and Europe. Over the years, we have created a portfolio of biosimilar products that are being marketed in several emerging markets. The launch of our pegfilgrastim through our collaborator in the U.S. in 2023, and bevacizumab in the United Kingdom last year marked the start of our biosimilars journey in regulated markets. Last year, we also signed a collaboration with Alvotech for the commercialization of their denosumab biosimilar in the U.S. and Europe. This latest collaboration with Henlius further progresses our regulated markets journey in biosimilars. Additionally, oncology has been a top focus therapy area for us. We look forward to leveraging our strong commercial capabilities in these markets to ensure patients receive access to best-in-class therapies and affordable treatment options.”

“This collaboration with Dr. Reddy’s on HLX15 is a significant step in our response to global health needs and improving access to advanced biologics,” said Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius. “Dr. Reddy’s has a long-standing dedication to oncology, driven by the purpose of ‘Good Health Can’t Wait’, and is committed to timely access to affordable and high-quality medicines, which complement Henlius’ focus on addressing unmet medical needs in research and development. We are confident that this partnership will enhance the global market competitiveness of both organizations in oncology treatment, ultimately allowing us to reach and support more patients around the world.”

About HLX15:

HLX15 is a fully human anti-CD38 IgG1κ monoclonal antibody independently developed by Henlius, and is a biosimilar candidate to Darzalex® & Darzalex Faspro®*. In accordance with the biosimilar guidelines of NMPA, EMA, and USFDA, HLX15 is being developed following the principles of stepwise development. HLX15 and reference daratumumab are considered comparable based on analytical similarity assessment and pre-clinical studies. In June 2024, the Phase 1 clinical study (NCT05679258) of HLX15 was successfully completed, meeting its primary endpoint. The findings indicate that HLX15 had similar pharmacokinetic characteristics, as well as comparable safety and immunogenicity profiles to the US-, EU-, and CN-sourced daratumumab. Comparative efficacy studies are currently underway.

*Darzalex® & Darzalex Faspro® are registered trademarks of Johnson & Johnson.

About Henlius: Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in the EU), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets. To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein.

INVESTOR RELATIONS

RICHA PERIWAL

[email protected]

MEDIA RELATIONS

USHA IYER

[email protected]

KEYWORDS: North America United States Asia Pacific Europe India

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Pharmaceutical Oncology Health Diabetes

MEDIA:

Logo
Logo

Charles Blankenship Elected to Fluor’s Board of Directors

Charles Blankenship Elected to Fluor’s Board of Directors

IRVING, Texas–(BUSINESS WIRE)–Fluor Corporation (NYSE: FLR) announced today that Charles (Chip) P. Blankenship Jr., Chairman and Chief Executive Officer (CEO) of Woodward Inc., a global energy control solutions company, has been elected to its Board of Directors effective March 1, 2025. Blankenship will serve on the Board’s Audit Committee and the Commercial Strategies and Operational Risk Committee, bringing the total number of Fluor Board members to 11, of whom 10 are independent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250206282258/en/

Charles Blankenship (Photo: Business Wire)

Charles Blankenship (Photo: Business Wire)

“With Chip Blankenship’s appointment to Fluor’s Board of Directors, the company gains another distinguished advisor and business leader, known for his transformative leadership in the industrial and aerospace sectors,” said David E. Constable, Chairman and Chief Executive Officer of Fluor. “Chip’s strategic and operational expertise, paired with his ability to drive innovation, will support Fluor’s growth as we pursue opportunities in advanced manufacturing, life sciences, mining, chemicals and the energy markets, among others.”

Prior to becoming Woodward’s CEO in May 2022, Blankenship’s leadership roles included serving as CEO of Arconic, an aerospace advanced alloys and components company, and a 24-year career at General Electric (GE). While at GE, he held significant leadership roles in aviation, energy and appliances, including CEO of GE Appliances and Vice President and General Manager of Commercial Aircraft Engines. He was also General Manager of GE’s Aero Energy.

Blankenship serves on the Board of Directors of the National Association of Manufacturers and the Board of Governors of the Aerospace Industries Association. He is a member of the National Academy of Engineering and served as the Montgomery Distinguished Professor of Practice at the University of Virginia (UVA) School of Engineering and Applied Sciences.

Blankenship holds a Ph.D. in materials science and engineering from UVA and a bachelor’s degree from Virginia Polytechnic Institute and State University.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s nearly 34,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $15.5 billion in 2023 and is ranked 265 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than a century. For more information, please visit www.fluor.com or follow Fluor on Facebook, Instagram, LinkedIn, X and YouTube.

#corporate

Brett Turner

Media Relations

864.281.6976

Jason Landkamer

Investor Relations

469.398.7222

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Other Manufacturing Commercial Building & Real Estate Construction & Property Engineering Manufacturing Other Natural Resources Mining/Minerals Architecture Other Construction & Property Natural Resources

MEDIA:

Photo
Photo
Charles Blankenship (Photo: Business Wire)
Logo
Logo

Jacobs to Design Florida Water Treatment Plant Upgrades for PFAS Removal

PR Newswire

Modernizing drinking water infrastructure for treatment of long-lasting synthetic chemicals


DALLAS
, Feb. 6, 2025 /PRNewswire/ — Jacobs (NYSE: J) was selected by the City of Boynton Beach in South Florida to evaluate and design upgrades at two water treatment plants to remove per- and polyfluoroalkyl substances (PFAS) from the city’s groundwater supplies to comply with new U.S. federal drinking water regulations.

At a combined treatment capacity of 30 million gallons per day, the two plants provide drinking water to more than 112,000 people. In addition to addressing new PFAS regulations, the facility upgrades will replace aging infrastructure and meet the community’s growing demand for water.

“Considering potential federal compliance deadlines, we’re working with the City of Boynton Beach to help deliver an effective, long-term PFAS treatment and disposal solution,” said Jacobs Senior Vice President Katus Watson. “We’ve supported the city with their water system challenges for more than 40 years and look forward to planning and designing this next important project for the community.”

Jacobs will evaluate the city’s existing facilities to assess treatment capabilities for PFAS removal and develop a comprehensive facilities plan for the city’s treatment plants, associated source water supply and residuals management systems. Once the facilities plan is complete, Jacobs will design the improvements and provide construction management services. The city received a loan from Florida’s Drinking Water State Revolving Fund Program for project planning and design.

“We look forward to working with our long-time partner Jacobs on this once-in-a-generation project, which will define the city’s water supply system for decades to come,” said City of Boynton Beach Utilities Director Poonam Kalkat.

A global leader in PFAS research, assessment and treatment across the water, environmental and advanced manufacturing sectors, Jacobs delivers comprehensive solutions to the PFAS challenge. We have delivered long-term PFAS solutions for many clients including the City of Woodbury, Minnesota, the City of North Bay, Ontario, the U.S. Department of Defense and Australian Department of Defense.

At Jacobs, we’re challenging today to reinvent tomorrow – delivering outcomes and solutions for the world’s most complex challenges. With approximately $12 billion in annual revenue and a team of almost 45,000, we provide end-to-end services in advanced manufacturing, cities & places, energy, environmental, life sciences, transportation and water. From advisory and consulting, feasibility, planning, design, program and lifecycle management, we’re creating a more connected and sustainable world. See how at jacobs.com and connect with us on LinkedIn, Instagram, X and Facebook

Certain statements contained in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not directly relate to any historical or current fact. When used herein, words such as “expects,” “anticipates,” “believes,” “seeks,” “estimates,” “plans,” “intends,” “future,” “will,” “would,” “could,” “can,” “may,” and similar words are intended to identify forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations, as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements including, but not limited to, uncertainties as to the impact of the recently completed separation transaction pursuant to which we spun off and merged our Critical Missions Solutions and Cyber & Intelligence government services businesses with Amentum (together, “new Amentum”) on Jacobs’ and new Amentum’s businesses, the timing of the award of projects and funding and potential changes to the amounts provided for under the Infrastructure Investment and Jobs Act and other legislation and executive orders related to governmental spending, and changes in U.S. or foreign tax laws, statutes, rules, regulations or ordinances, including the impact of, and changes to tariffs or trade policies, that may adversely impact our future financial positions or results of operations, as well as general economic conditions, including inflation and the actions taken by monetary authorities in response to inflation, changes in interest rates and foreign currency exchange rates, changes in capital markets, the possibility of a recession or economic downturn, and increased uncertainty and risks, including policy risks and potential civil unrest, relating to the outcome of elections across our key markets and elevated geopolitical tension and conflicts, among others. For a description of these and additional factors that may occur that could cause actual results to differ from our forward-looking statements, see our filings with the U.S. Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.

For press/media inquiries:
[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jacobs-to-design-florida-water-treatment-plant-upgrades-for-pfas-removal-302369897.html

SOURCE Jacobs

Peabody Reports Results for the Quarter and Year Ended December 31, 2024

PR Newswire


Centurion Ships First Coal and Advances Towards Longwall Start in Q1 2026


Premium Hard Coking Coal Acquisition Poised to Reshape Peabody


ST. LOUIS
, Feb. 6, 2025 /PRNewswire/ — Peabody (NYSE: BTU) today reported fourth quarter net income attributable to common stockholders of $30.6 million, or $0.25 per diluted share, compared to $192.0 million, or $1.33 per diluted share, in the prior year quarter. Peabody had Adjusted EBITDA1 of $176.7 million in the fourth quarter of 2024 including a $41.4 million non-cash charge from Australia currency remeasurement, compared to $345.1 million in the fourth quarter of 2023.

Full-year 2024 revenue totaled $4,236.7 million compared to $4,946.7 million in the prior year. Full-year 2024 net income attributable to common stockholders totaled $370.9 million, or $2.70 per diluted share, compared to $759.6 million, or $5.00 per diluted share in the prior year. Adjusted EBITDA was $871.7 million compared to $1,363.9 million in the prior year. 

“Peabody completed a highly productive year with a strong fourth quarter performance and the advancement of a transformative acquisition that we are confident will reshape Peabody in a profound and positive way,” said Peabody President and Chief Executive Officer Jim Grech. “The Peabody team also drove an exceptional year in safety and environmental performance, leading to record low accident and severity rates and the reduction of more than $100 million of reclamation bonding obligations.”

____________________________

1 Adjusted EBITDA is a non-GAAP financial measure. Adjusted EBITDA margin is equal to segment Adjusted EBITDA (excluding insurance recoveries) divided by segment revenue. Revenue per Ton and Adjusted EBITDA Margin per Ton are equal to revenue by segment and Adjusted EBITDA by segment (excluding insurance recoveries), respectively, divided by segment tons sold. Costs per Ton is equal to Revenue per Ton less Adjusted EBITDA Margin per Ton. Management believes Costs per Ton and Adjusted EBITDA Margin per Ton best reflect controllable costs and operating results at the reporting segment level. We consider all measures reported on a per ton basis, as well as Adjusted EBITDA margin, to be operating/statistical measures. Please refer to the tables and related notes for a reconciliation and definition of non-GAAP financial measures.

Fourth Quarter and Full Year Highlights

  • Agreed to purchase four world-class premium hard coking coal operations in Australia’s Bowen Basin, which will transform the company to a predominately steelmaking-coal supplier.
  • Advanced the development of the premium hard coking coal Centurion Mine in Australia and shipped the first coal cargo, with longwall production expected to start March 2026.
  • Reported full-year Adjusted EBITDA of $872 million, operating cash flow from continuing operations of $613 million, and $700 million of Cash and Cash Equivalents at December 31, 2024.
  • Returned $221 million to shareholders in share repurchases and dividends.
  • Achieved a record low total reportable injury frequency rates (TRIFR) in U.S. and Australia operations, generating a combined global rate of 0.81 per 200,000 hours worked and also achieved the lowest recorded annual injury severity rate in company history.
  • Announced a partnership with leading renewable energy company RWE to grow the company’s R3 Renewables platform to develop solar and energy storage projects on repurposed reclaimed mine lands.
  • Achieved a company record $110 million in bond release approval for reclaimed U.S. lands. In addition, reclaimed lands exceeded disturbed lands by a ratio of 1.7 to 1, improving upon the prior best ratio of 1.3 to 1 in 2023.
  • Declared a $0.075 per share dividend on February 6, 2025.

Fourth Quarter Segment Performance



Seaborne Thermal


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023

Tons sold (in millions)

4.2

4.1

3.7

16.4

15.5


Export


2.8


2.6


2.6


10.6


10.0


Domestic


1.4


1.5


1.1


5.8


5.5

Revenue per Ton

$             73.55

$             76.21

$             76.22

$             73.88

$             85.94


Export – Avg. Realized Price per Ton


96.41


105.51


97.20


99.87


119.79


Domestic – Avg. Realized Price per Ton


25.47


25.36


30.26


25.96


24.73

Costs per Ton

46.97

47.01

49.71

47.71

48.66


Adjusted EBITDA Margin per Ton


$             26.58


$             29.20


$             26.51


$             26.17


$             37.28


Adjusted EBITDA (in millions)


$             111.8


$             120.0


$               99.8


$             430.0


$             576.8

Seaborne Thermal volume totaled 4.2 million tons, ahead of expectations, primarily driven by higher production at Wambo Underground. The average realized export price of $96.41 per ton was down from $105.51 in the prior quarter impacted by sales mix, while costs remained largely stable. The segment reported 36 percent Adjusted EBITDA margins on Adjusted EBITDA of $111.8 million.  



Seaborne Metallurgical


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023

Tons sold (in millions)

2.2

1.7

2.1

7.3

6.9

Revenue per Ton

$           123.41

$           144.60

$           186.74

$           144.97

$           188.66

Costs per Ton

113.05

128.04

107.89

122.77

125.18


Adjusted EBITDA Margin per Ton


$             10.36


$             16.56


$             78.85


$             22.20


$             63.48


Adjusted EBITDA, Excluding Insurance Recovery (in millions)


$               22.8


$               27.8


$             166.2


$             161.7


$             438.1


Shoal Creek Insurance Recovery (in millions)








80.8




Adjusted EBITDA (in millions)


$               22.8


$               27.8


$             166.2


$             242.5


$             438.1

Seaborne Metallurgical volumes came in largely in line with expectations at 2.2 million tons, reflecting a 29 percent increase over the prior quarter. Strong production at Shoal Creek drove a 12 percent reduction in segment costs per ton to $113.05, beating expectations. The average realized price of $123.41 per ton was 15 percent lower than the prior quarter, reflecting a higher mix of Shoal Creek sales and generally lower market pricing. The segment reported 8 percent Adjusted EBITDA margins on Adjusted EBITDA of $22.8 million



Powder River Basin


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023

Tons sold (in millions)

23.0

22.1

23.6

79.6

87.2

Revenue per Ton

$             13.79

$             13.84

$             13.58

$             13.81

$             13.74

Costs per Ton

11.50

11.50

11.98

12.07

11.98


Adjusted EBITDA Margin per Ton


$               2.29


$               2.34


$               1.60


$               1.74


$               1.76


Adjusted EBITDA (in millions)


$               52.7


$               51.7


$               37.6


$             138.6


$             153.7

Powder River Basin (PRB) shipped 23.0 million tons, 1.8 million tons ahead of expectations and the highest quarterly sales volume for the year. PRB average realized price and costs per ton remained stable with the previous quarter. The segment reported 17 percent Adjusted EBITDA margins on Adjusted EBITDA of $52.7 million.



Other U.S. Thermal


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023

Tons sold (in millions)

3.7

4.0

3.7

14.6

16.2

Revenue per Ton

$             57.74

$             53.52

$             57.00

$             56.38

$             54.77

Costs per Ton

46.73

46.50

45.57

46.04

41.98


Adjusted EBITDA Margin per Ton


$             11.01


$               7.02


$             11.43


$             10.34


$             12.79


Adjusted EBITDA (in millions)


$               40.5


$               28.4


$               42.3


$             150.8


$             207.5

Other U.S. Thermal shipped 3.7 million tons in the quarter, modestly below expectations and the previous quarter due to geologic challenges at Twentymile that are expected to be resolved in the first quarter of 2025. Revenue per ton was higher than anticipated due to sales contract cancellation settlements, increasing segment margin. Costs were largely stable with the previous quarter. The segment reported 19 percent Adjusted EBITDA margins and Adjusted EBITDA of $40.5 million.

Update on Centurion and Premium Hard Coking Coal Acquisition

“It’s hard to overstate the benefits to Peabody, both strategically and financially, from the ramp up of Centurion as well as the agreement to acquire multiple premium hard coking coal mines in Australia,” said Mr. Grech. “We are confident that these assets will positively redefine Peabody in the market.”

During the fourth quarter, Peabody reached several key milestones at Centurion. The mine is ahead of its development schedule and now has four continuous miners in coal production, while shipping its first coal in December, serving a growing steel producer in Southeast Asia. The company expects to begin producing continuous miner coal from Centurion North early in the third quarter, and targets a combined 500 thousand tons of production for the full year. Peabody is on track to begin longwall production in March 2026, producing 3.5 million tons of premium hard coking coal next year. With a planned annual production averaging 4.7 million tons and approximately 140 million tons of reserves, the operation has a mine life of more than 25 years.

Peabody’s acquisition of multiple coal mines from Anglo American is progressing, with completion now targeted for next quarter subject to closing conditions. The company has several regulatory approvals in hand from key governmental agencies, the pre-emption rights timetable window is advancing, Anglo’s operational improvements are underway, the permanent financing process has begun, and minority stake ownership discussions are ongoing.

During the first full year of ownership in 2026, the premium hard coking coal mines are expected to produce 11.3 million tons of coal at fully loaded costs of $130$140 per ton.

Capital Allocation

Peabody generated $612.8 million in operating cash flows from continuing operations in 2024. The company returned $220.7 million to shareholders, invested $226.8 million in the development of Centurion and acquired the Centurion North coal reserves for $143.8 million.

“Peabody’s capital allocation strategy continues to reflect a balanced approach of shareholder returns and reinvestment in the business,” said Executive Vice President and Chief Financial Officer Mark Spurbeck. “Looking ahead, we have structured our pending acquisition with flexible consideration arrangements, including upfront, deferred and contingent payments, to enable the cash flows from the new assets to fund the acquisition.”

Focus Areas for 2025

“Peabody is transforming into a predominately metallurgical coal producer, with substantially higher long-term earnings potential, a recharged asset base, and a three-pronged value creation model via free cash flow growth per share, shareholder returns, and multiple expansion,” said Mr. Grech.

Peabody has identified five areas of focus in 2025:

  • Continuing emphasis on safe, productive, environmentally sound operations
  • Ramping up the Centurion Mine on time and on budget
  • Successfully completing the premium hard coking coal acquisition and integrating the mines into Peabody
  • Serving growing Asian thermal coal demand through its low-cost Australian export platform
  • Leveraging Peabody’s low-cost domestic U.S. thermal coal production to capitalize on emerging favorable policy and economic themes

First Quarter 2025 Outlook   

Seaborne Thermal

  • Volumes are expected to be 4.0 million tons, including 2.5 million export tons. 0.2 million export tons are priced at $108 per ton, and 1.3 million tons of Newcastle product and 1.0 million tons of high ash product are unpriced. Costs are anticipated to be $45$50 per ton.

Seaborne Metallurgical

  • Seaborne met volumes are expected to be 2.0 million tons and are expected to achieve 70 to 75 percent of the premium hard coking coal price index. Costs are anticipated to be temporarily elevated at $125$135 per ton reflecting a planned longwall move at Shoal Creek.

U.S. Thermal

  • PRB volume is expected to be approximately 19 million tons at an average price of $13.80 per ton and costs of approximately $12.00$12.75 per ton.
  • Other U.S. Thermal volume is expected to be approximately 3.4 million tons at an average price of $52.50 per ton and costs of approximately $43$47 per ton.

Today’s earnings call is scheduled for 10 a.m. CT and can be accessed via the company’s website at PeabodyEnergy.com.

Peabody (NYSE: BTU) is a leading coal producer, providing essential products for the production of affordable, reliable energy and steel.  Our commitment to sustainability underpins everything we do and shapes our strategy for the future.  For further information, visit PeabodyEnergy.com. 

Contact:

Vic Svec

[email protected]

 

Guidance Targets (Excluding Contributions from Planned Acquisition)



Segment Performance


2025 Full Year


Total Volume
(millions of


short tons)


Priced Volume
(millions of short
tons)


Priced Volume
Pricing per
Short Ton


Average Cost per
Short Ton

Seaborne Thermal

14.2 – 15.2

5.6

$30.86

$47.00 – $52.00

Seaborne Thermal (Export)

8.8 – 9.8

0.2

$108.00

NA

Seaborne Thermal (Domestic)

5.4

5.4

$28.00

NA

Seaborne Metallurgical

8.0 – 9.0

0.5

$128.00

$120.00 – $130.00

PRB U.S. Thermal

72 – 78

71

$13.85

$12.00 – $12.75

Other U.S. Thermal

13.4 -14.4

13.6

$52.00

$43.00 – $47.00



Other Annual Financial Metrics ($ in millions)


2025 Full Year

SG&A

$95

Total Capital Expenditures

$450

Major Project Capital Expenditures

$280

Sustaining Capital Expenditures

$170

ARO Cash Spend

$50



Supplemental Information

Seaborne Thermal

54% of unpriced export volumes are expected to price on average at Globalcoal “NEWC” levels and 46% are expected to have a higher ash content and price at 80-95% of API 5 price levels.

Seaborne Metallurgical

On average, Peabody’s metallurgical sales are anticipated to price at 70-75% of the premium hard-coking coal index price (FOB Australia).

PRB and Other U.S. Thermal

PRB and Other U.S. Thermal volumes reflect volumes priced at December 31, 2024. Weighted average quality for the PRB segment 2025 volume is approximately 8,685 BTU.

Certain forward-looking measures and metrics presented are non-GAAP financial and operating/statistical measures. Due to the volatility and variability of certain items needed to reconcile these measures to their nearest GAAP measure, no reconciliation can be provided without unreasonable cost or effort.


Condensed Consolidated Statements of Operations (Unaudited)


For the Quarters Ended Dec. 31, 2024, Sept. 30, 2024 and Dec. 31, 2023 and the Years Ended Dec. 31, 2024 and 2023

(In Millions, Except Per Share Data)


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023

Tons Sold

33.1

31.9

33.2

118.0

126.2

Revenue

$          1,123.1

$          1,088.0

$          1,235.0

$          4,236.7

$          4,946.7

Operating Costs and Expenses (1)

957.0

845.8

872.8

3,420.9

3,385.1

Depreciation, Depletion and Amortization

95.6

84.7

82.2

343.0

321.4

Asset Retirement Obligation Expenses

10.2

12.9

4.2

48.9

50.5

Selling and Administrative Expenses

26.3

20.6

24.7

91.0

90.7

Restructuring Charges

2.3

1.9

0.3

4.4

3.3

Transaction Costs Related to Business Combinations

10.3

10.3

Other Operating Loss (Income):

Net Gain on Disposals

(0.1)

(0.1)

(6.5)

(9.8)

(15.0)

Asset Impairment

2.0

Provision for NARM and Shoal Creek Losses

3.9

3.7

40.9

Shoal Creek Insurance Recovery

(109.5)

(Income) Loss from Equity Affiliates

(18.6)

2.1

2.8

(11.5)

(6.9)

Operating Profit

40.1

120.1

250.6

445.3

1,074.7

Interest Expense, Net of Capitalized Interest

11.8

9.7

14.3

46.9

59.8

Net Loss on Early Debt Extinguishment

8.8

Interest Income

(17.3)

(17.7)

(20.3)

(71.0)

(76.8)

Net Periodic Benefit Credit, Excluding Service Cost

(10.2)

(10.1)

(12.2)

(40.6)

(41.6)

Net Mark-to-Market Adjustment on Actuarially Determined Liabilities

(6.1)

(0.3)

(6.1)

(0.3)

Income from Continuing Operations Before Income Taxes

61.9

138.2

269.1

516.1

1,124.8

Income Tax Provision

23.6

25.7

70.1

108.8

308.8

Income from Continuing Operations, Net of Income Taxes

38.3

112.5

199.0

407.3

816.0

Loss from Discontinued Operations, Net of Income Taxes

(0.5)

(1.0)

(0.3)

(3.8)

(0.4)

Net Income

37.8

111.5

198.7

403.5

815.6

Less: Net Income Attributable to Noncontrolling Interests

7.2

10.2

6.7

32.6

56.0

Net Income Attributable to Common Stockholders

$               30.6

$             101.3

$             192.0

$             370.9

$             759.6

Adjusted EBITDA (2)

$             176.7

$             224.8

$             345.1

$             871.7

$          1,363.9

Diluted EPS – Income from Continuing Operations (3)(4)

$               0.25

$               0.74

$               1.33

$               2.73

$               5.00

Diluted EPS – Net Income Attributable to Common Stockholders (3)

$               0.25

$               0.74

$               1.33

$               2.70

$               5.00

(1)

Excludes items shown separately.

(2)

Adjusted EBITDA is a non-GAAP financial measure. Refer to the “Reconciliation of Non-GAAP Financial Measures” section in this document for definitions and reconciliations to the most comparable measures under U.S. GAAP.

(3)

Weighted average diluted shares outstanding were 138.4 million, 141.6 million and 147.2 million during the quarters ended December 31, 2024, September 30, 2024 and December 31, 2023, respectively. During the years ended December 31, 2024 and 2023, weighted average diluted shares outstanding were 141.9 million and 154.3 million, respectively.

(4)

Reflects income from continuing operations, net of income taxes less net income attributable to noncontrolling interests.


This information is intended to be reviewed in conjunction with the company’s filings with the SEC.

 


Condensed Consolidated Balance Sheets


As of Dec. 31, 2024 and 2023

(Dollars In Millions)


(Unaudited)


Dec. 31, 2024


Dec. 31, 2023

Cash and Cash Equivalents

$               700.4

$               969.3

Accounts Receivable, Net

359.3

389.7

Inventories, Net

393.4

351.8

Other Current Assets

327.6

308.9

Total Current Assets

1,780.7

2,019.7

Property, Plant, Equipment and Mine Development, Net

3,081.5

2,844.1

Operating Lease Right-of-Use Assets

119.3

61.9

Restricted Cash and Collateral

809.8

957.6

Investments and Other Assets

162.4

78.8

Total Assets

$            5,953.7

$             5,962.1

Current Portion of Long-Term Debt

$                 15.8

$                 13.5

Accounts Payable and Accrued Expenses

811.7

965.5

Total Current Liabilities

827.5

979.0

Long-Term Debt, Less Current Portion

332.3

320.7

Deferred Income Taxes

40.9

28.6

Asset Retirement Obligations, Less Current Portion

667.8

648.6

Accrued Postretirement Benefit Costs

120.4

148.4

Operating Lease Liabilities, Less Current Portion

86.7

47.7

Other Noncurrent Liabilities

169.3

181.6

Total Liabilities

2,244.9

2,354.6

Common Stock

1.9

1.9

Additional Paid-in Capital

3,990.5

3,983.0

Treasury Stock

(1,926.5)

(1,740.2)

Retained Earnings

1,445.8

1,112.7

Accumulated Other Comprehensive Income

138.8

189.6

Peabody Energy Corporation Stockholders’ Equity

3,650.5

3,547.0

Noncontrolling Interests

58.3

60.5

Total Stockholders’ Equity

3,708.8

3,607.5

Total Liabilities and Stockholders’ Equity

$            5,953.7

$             5,962.1


This information is intended to be reviewed in conjunction with the company’s filings with the SEC.

 


Condensed Consolidated Statements of Cash Flows (Unaudited)


For the Quarters Ended Dec. 31, 2024, Sept. 30, 2024 and Dec. 31, 2023 and the Years Ended Dec. 31, 2024 and 2023

(Dollars In Millions)


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023


Cash Flows From Operating Activities


Net Cash Provided By Continuing Operations

$          121.4

$          361.4

$          283.6

$          612.8

$       1,116.3

Net Cash Used in Discontinued Operations

(1.6)

(1.5)

(1.2)

(6.3)

(80.8)


Net Cash Provided By Operating Activities

119.8

359.9

282.4

606.5

1,035.5


Cash Flows From Investing Activities

Additions to Property, Plant, Equipment and Mine Development

(135.6)

(98.7)

(157.9)

(401.3)

(348.3)

Changes in Accrued Expenses Related to Capital Expenditures

5.3

7.2

8.0

(1.2)

2.9

Wards Well Acquisition

(143.8)

Deposit Associated with Planned Acquisition

(75.0)

(75.0)

Insurance Proceeds Attributable to Shoal Creek Equipment Losses

5.3

10.9

Proceeds from Disposal of Assets, Net of Receivables

1.0

0.6

8.9

17.1

22.8

Contributions to Joint Ventures

(177.9)

(176.6)

(168.2)

(728.0)

(741.6)

Distributions from Joint Ventures

167.4

189.2

142.3

717.2

721.7

Other, Net

6.3

0.2

(1.1)

6.0

(0.1)


Net Cash Used In Investing Activities

(208.5)

(72.8)

(168.0)

(598.1)

(342.6)


Cash Flows From Financing Activities

Proceeds from Loan Note Related to Planned Acquisition

9.3

9.3

Repayments of Long-Term Debt

(3.2)

(2.6)

(2.1)

(10.4)

(9.0)

Payment of Debt Issuance and Other Deferred Financing Costs

(0.9)

(12.0)

(0.3)

Common Stock Repurchases

(100.0)

(83.7)

(183.1)

(347.7)

Excise Taxes Paid Related to Common Stock Repurchases

(3.3)

(3.3)

Repurchase of Employee Common Stock Relinquished for Tax Withholding

(4.1)

(13.7)

Dividends Paid

(9.1)

(9.4)

(9.9)

(37.6)

(30.6)

Distributions to Noncontrolling Interests

(16.3)

(0.1)

(34.8)

(59.0)


Net Cash Used In Financing Activities

(7.2)

(128.3)

(95.8)

(276.0)

(460.3)


Net Change in Cash, Cash Equivalents and Restricted Cash

(95.9)

158.8

18.6

(267.6)

232.6


Cash, Cash Equivalents and Restricted Cash at Beginning of Period

1,478.5

1,319.7

1,631.6

1,650.2

1,417.6


Cash, Cash Equivalents and Restricted Cash at End of Period

$       1,382.6

$       1,478.5

$       1,650.2

$       1,382.6

$       1,650.2


This information is intended to be reviewed in conjunction with the company’s filings with the SEC.

 


Reconciliation of Non-GAAP Financial Measures (Unaudited)


For the Quarters Ended Dec. 31, 2024, Sept. 30, 2024 and Dec. 31, 2023 and the Years Ended Dec. 31, 2024 and 2023

(Dollars In Millions)


Note: Management believes that non-GAAP performance measures are used by investors to measure our operating performance. These measures are not intended to serve as alternatives to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023

Income from Continuing Operations, Net of Income Taxes

$            38.3

$          112.5

$          199.0

$          407.3

$          816.0

Depreciation, Depletion and Amortization

95.6

84.7

82.2

343.0

321.4

Asset Retirement Obligation Expenses

10.2

12.9

4.2

48.9

50.5

Restructuring Charges

2.3

1.9

0.3

4.4

3.3

Transaction Costs Related to Business Combinations

10.3

10.3

Asset Impairment

2.0

Provision for NARM and Shoal Creek Losses

3.9

3.7

40.9

Shoal Creek Insurance Recovery – Property Damage

(28.7)

Changes in Amortization of Basis Difference Related to Equity Affiliates

(0.7)

(0.4)

(0.4)

(1.8)

(1.6)

Interest Expense, Net of Capitalized Interest

11.8

9.7

14.3

46.9

59.8

Net Loss on Early Debt Extinguishment

8.8

Interest Income

(17.3)

(17.7)

(20.3)

(71.0)

(76.8)

Net Mark-to-Market Adjustment on Actuarially Determined Liabilities

(6.1)

(0.3)

(6.1)

(0.3)

Unrealized Gains on Derivative Contracts Related to Forecasted Sales

(159.0)

Unrealized Losses (Gains) on Foreign Currency Option Contracts

9.4

(3.7)

(7.3)

9.0

(7.4)

Take-or-Pay Contract-Based Intangible Recognition

(0.7)

(0.8)

(0.6)

(3.0)

(2.5)

Income Tax Provision

23.6

25.7

70.1

108.8

308.8

Adjusted EBITDA (1)

$          176.7

$          224.8

$          345.1

$          871.7

$        1,363.9

Operating Costs and Expenses

$          957.0

$          845.8

$          872.8

$        3,420.9

$        3,385.1

Unrealized (Losses) Gains on Foreign Currency Option Contracts

(9.4)

3.7

7.3

(9.0)

7.4

Take-or-Pay Contract-Based Intangible Recognition

0.7

0.8

0.6

3.0

2.5

Net Periodic Benefit Credit, Excluding Service Cost

(10.2)

(10.1)

(12.2)

(40.6)

(41.6)

Total Reporting Segment Costs (2)

$          938.1

$          840.2

$          868.5

$        3,374.3

$        3,353.4

(1)

Adjusted EBITDA is defined as income from continuing operations before deducting net interest expense, income taxes, asset retirement obligation expenses and depreciation, depletion and amortization. Adjusted EBITDA is also adjusted for the discrete items that management excluded in analyzing each of our segment’s operating performance as displayed in the reconciliation above. Adjusted EBITDA is used by management as the primary metric to measure each of our segment’s operating performance and allocate resources.

(2)

Total Reporting Segment Costs is defined as operating costs and expenses adjusted for the discrete items that management excluded in analyzing each of our segment’s operating performance, as displayed in the reconciliation above. Total Reporting Segment Costs is used by management as a component of a metric to measure each of our segment’s operating performance.


This information is intended to be reviewed in conjunction with the company’s filings with the SEC.

 


Supplemental Financial Data (Unaudited)


For the Quarters Ended Dec. 31, 2024, Sept. 30, 2024 and Dec. 31, 2023 and the Years Ended Dec. 31, 2024 and 2023


Quarter Ended


Year Ended


Dec.


Sept.


Dec.


Dec.


Dec.


2024


2024


2023


2024


2023


Revenue Summary (In Millions)

Seaborne Thermal

$          309.3

$          313.2

$          286.3

$          1,213.9

$          1,329.7

Seaborne Metallurgical

271.8

242.5

394.0

1,055.6

1,301.9

Powder River Basin

317.5

305.3

320.1

1,098.8

1,198.1

Other U.S. Thermal

212.3

216.7

210.7

822.6

888.2

Total U.S. Thermal

529.8

522.0

530.8

1,921.4

2,086.3

Corporate and Other

12.2

10.3

23.9

45.8

228.8

Total

$        1,123.1

$        1,088.0

$        1,235.0

$          4,236.7

$          4,946.7


Total Reporting Segment Costs Summary (In Millions)
(1)

Seaborne Thermal

$          197.5

$          193.2

$          186.5

$             783.9

$             752.9

Seaborne Metallurgical

249.0

214.7

227.8

893.9

863.8

Powder River Basin

264.8

253.6

282.5

960.2

1,044.4

Other U.S. Thermal

171.8

188.3

168.4

671.8

680.7

Total U.S. Thermal

436.6

441.9

450.9

1,632.0

1,725.1

Corporate and Other

55.0

(9.6)

3.3

64.5

11.6

Total

$          938.1

$          840.2

$          868.5

$          3,374.3

$          3,353.4


Other Supplemental Financial Data (In Millions)

Adjusted EBITDA – Seaborne Thermal

$          111.8

$          120.0

$            99.8

$             430.0

$             576.8

Adjusted EBITDA – Seaborne Metallurgical, Excluding Shoal Creek Insurance Recovery

22.8

27.8

166.2

161.7

438.1

Shoal Creek Insurance Recovery – Business Interruption

80.8

Adjusted EBITDA – Seaborne Metallurgical

22.8

27.8

166.2

242.5

438.1

Adjusted EBITDA – Powder River Basin

52.7

51.7

37.6

138.6

153.7

Adjusted EBITDA – Other U.S. Thermal

40.5

28.4

42.3

150.8

207.5

Adjusted EBITDA – Total U.S. Thermal

93.2

80.1

79.9

289.4

361.2

Middlemount

10.2

1.8

(0.5)

13.1

13.2

Resource Management Results (2)

2.7

2.2

9.6

19.2

21.0

Selling and Administrative Expenses

(26.3)

(20.6)

(24.7)

(91.0)

(90.7)

Other Operating Costs, Net (3)

(37.7)

13.5

14.8

(31.5)

44.3

Adjusted EBITDA (1)

$          176.7

$          224.8

$          345.1

$             871.7

$          1,363.9

(1)

Total Reporting Segment Costs and Adjusted EBITDA are non-GAAP financial measures. Refer to the “Reconciliation of Non-GAAP Financial Measures” section in this document for definitions and reconciliations to the most comparable measures under U.S. GAAP.

(2)

Includes gains (losses) on certain surplus coal reserve and surface land sales and property management costs and revenue.

(3)

Includes trading and brokerage activities, costs associated with post-mining activities, gains (losses) on certain asset disposals, minimum charges on certain transportation-related contracts, results from the Company’s equity method investment in renewable energy joint ventures, costs associated with suspended operations including the Centurion Mine, the impact of foreign currency remeasurement, expenses related to the Company’s other commercial activities and revenue of $6.7 million and $25.9 million related to the assignment of port and rail capacity during the quarter and year ended December 31, 2023, respectively.


This information is intended to be reviewed in conjunction with the company’s filings with the SEC.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the securities laws. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words or variation of words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “targets,” “would,” “will,” “should,” “goal,” “could” or “may” or other similar expressions. Forward-looking statements provide management’s or the Board’s current expectations or predictions of future conditions, events, or results. All statements that address operating performance, events, or developments that may occur in the future are forward-looking statements, including statements regarding the shareholder return framework, execution of the Company’s operating plans, market conditions for the Company’s products, reclamation obligations, financial outlook, potential acquisitions and strategic investments, and liquidity requirements. All forward-looking statements speak only as of the date they are made and reflect Peabody’s good faith beliefs, assumptions, and expectations, but they are not guarantees of future performance or events. Furthermore, Peabody disclaims any obligation to publicly update or revise any forward-looking statement, except as required by law. By their nature, forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Factors that might cause such differences include, but are not limited to, a variety of economic, competitive, and regulatory factors, many of which are beyond Peabody’s control, that are described in Peabody’s periodic reports filed with the SEC including its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended Jun. 30, 2024, and other factors that Peabody may describe from time to time in other filings with the SEC. You may get such filings for free at Peabody’s website at www.peabodyenergy.com. You should understand that it is not possible to predict or identify all such factors and, consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/peabody-reports-results-for-the-quarter-and-year-ended-december-31-2024-302369546.html

SOURCE Peabody

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia

on track for mid-2025

Right-sizing commercial efforts to optimize XOLREMDI promotion and

support U.S. WHIM syndrome community

Restructuring impact expected to extend cash runway into first half of 2026

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, announced today a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat those with chronic neutropenia, while also optimizing its U.S. promotion of XOLREMDI® (mavorixafor), approved for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare immunodeficiency.

Strategic restructuring activities include:

  • Reducing overall headcount by 43 people (approximately 30% of X4 employees), which includes discontinuing research efforts and closing the company’s facility in Vienna, Austria, as well as pausing pre-clinical drug candidate programs;
  • Scaling the U.S. commercial field team and supporting roles across the company;
  • Streamlining other spending to support the ongoing clinical development of mavorixafor for the larger population of those with chronic neutropenia.

“This strategic restructuring is being implemented to improve our operational efficiency and capital efficiency as we continue to maximize the global market opportunity for mavorixafor and to benefit the largest number of patients we can worldwide,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “We expect this organizational redesign to sharpen our focus on the execution of our ongoing global pivotal Phase 3 clinical trial of mavorixafor in chronic neutropenia while we continue to build WHIM communities through both our U.S. commercial presence and through global partnerships. We would like to express our gratitude to all of the X4tizens being impacted by this restructuring. Their contributions and dedication have not only helped shape who we are as a company today, but, we believe, will continue to positively impact the immunodeficiency community for years to come.”

X4 expects its efforts will decrease annual spending by $30-35 million and believes it will have sufficient funds to support operations into the first half of 2026. Workforce reductions are expected to be completed in the first quarter of 2025.

About X4 Pharmaceuticals

X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4’s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding X4’s future financial performance and position, business strategy, and plans and objectives for future operations; the timing, execution, and expected impact of X4’s restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; X4’s commercial plans and strategy for mavorixafor; the expected sufficiency of X4’s existing cash resources; the internal and external costs required for X4’s ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of X4’s plans or both; X4’s ability to advance and commercialize mavorixafor to treat chronic neutropenia or to optimize the U.S. promotion of XOLREMDI® (mavorixafor), approved for the treatment of WHIM; the initiation, timing, progress, and results of X4’s current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of trials will become available, as well as X4’s research and development programs. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: X4’s restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; X4’s ability to execute their clinical development plans for mavorixafor to treat chronic neutropenia, including the timing, costs, and results of X4’s pivotal Phase 3 trial; X4 may not be able to obtain regulatory approval for, or successfully commercialize, mavorixafor or any other product candidate for other chronic neutropenic disorders or any other potential indication; X4’s reliance on third parties, including global partnership arrangements; X4’s ability to manage operating expenses and our estimates regarding capital requirements; changes in global economic, business, competitive or regulatory conditions; X4 may have difficulty establishing and maintaining an effective sales and marketing organization or suitable third-party alternatives for any approved products; the expected availability, content, and timing of clinical data from X4’s ongoing clinical trials of mavorixafor may be delayed or unavailable, including X4’s ongoing Phase 3 clinical trial; the design and rate of enrollment for clinical trials, including the current design of a Phase 3 clinical trial evaluating mavorixafor in certain chronic neutropenic disorders may not enable successful completion of the trial(s); X4 may be unable to obtain and maintain regulatory approvals; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s Quarterly Report on X4’s Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 13, 2024, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

X4 Investor Contact:

Daniel Ferry
Managing Director, LifeSci Advisors
[email protected]
(617) 430-7576

X4 Media Contact:

Rhiannon Jeselonis
Ten Bridge Communications
[email protected]



Intercontinental Exchange Announces 7% Increase to its Quarterly Dividend

Intercontinental Exchange Announces 7% Increase to its Quarterly Dividend

ATLANTA & NEW YORK–(BUSINESS WIRE)–
Intercontinental Exchange (NYSE: ICE), a leading global provider of technology and data, announced board authorization of its first quarter 2025 dividend of $0.48 per share, up 7% from its previous $0.45 per share quarterly dividend in 2024.

The first quarter cash dividend is payable on March 31, 2025 to stockholders of record as of March 17, 2025. The ex-dividend date is March 17, 2025.

ICE expects the annual total dividend for 2025 to be $1.92 per share. The expected record and payable dates for the balance of the year are expected to be as noted below, subject to board authorization.

Record Date

             

Payable Date

March 17, 2025

             

March 31, 2025

June 13, 2025

             

June 30, 2025

September 16, 2025

             

September 30, 2025

December 16, 2025

             

December 31, 2025

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds, and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE’s futures, equity, and options exchanges — including the New York Stock Exchange — and clearing houses help people invest, raise capital and manage risk. We offer some of the world’s largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology, we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines, and automates industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).”

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 — Statements in this press release regarding ICE’s business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE’s Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 6, 2025.

SOURCE: Intercontinental Exchange

ICE-CORP

Category: Corporate

ICE Investor Relations Contact:

Katia Gonzalez

+1 678 981 3882

[email protected]

[email protected]

ICE Media Contact:

Damon Leavell

+1 212 323 8587

[email protected]

[email protected]

KEYWORDS: United States North America New York Georgia

INDUSTRY KEYWORDS: Data Analytics Finance Asset Management Banking Data Management Professional Services Technology Fintech

MEDIA:

Logo
Logo